Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer’s Disease: A Systematic Review and Meta-Analysis

• Published in: The journal of prevention of Alzheimer's disease Vol. 11; no. 3; pp. 721 - 729
• Main Authors: Zakariaee, Seyed Salman, Naderi, N., Azizi, E.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 2024
• Subjects: Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Geriatrics/Gerontology; Humans; Medicine; Medicine & Public Health; Neurology; Review; Vascular Endothelial Growth Factor A - blood; Vascular Endothelial Growth Factor A - cerebrospinal fluid; Vascular endothelial growth factor; Alzheimer; VEGF; Dementia; dementia
• ISSN: 2426-0266
• DOI: 10.14283/jpad.2024.18

Background
Alzheimer’s disease (AD) is a progressive neurodegenerative illness that leads to impairment of cognitive functions and memory loss. Even though there is a plethora of research reporting the abnormal regulation of VEGF expression in AD pathogenesis, whether the CSF and serum VEGF are increased in AD is an open question yet. In this study, the association of CSF and serum VEGF concentrations with the risk of Alzheimer’s disease was investigated using systematic review and meta-analysis.
Methods
A systematic literature search was carried out using online specialized biomedical databases of Web of Science, Pubmed, Scopus, Embase, and Google Scholar until Feb 2023 without restriction to the beginning time. The meta-analysis was performed using the random-effects model and only case-control publications describing VEGF concentrations in Alzheimer’s patients were considered for calculating the pooled effect size.
Results
In the systematic literature search, 6 and 13 studies met the inclusion criteria to evaluate CSF and serum VEGF concentrations of Alzheimer’s patients, respectively. This meta-analysis retrieved a total number of 2380 Alzheimer’s patients and 5368 healthy controls. Under the random-effects model in the meta-analysis, the pooled SMD for CSF and serum VEGF concentrations of Alzheimer’s patients were −0.13 (95%CI,−0.42–0.16) and 0.23 (95%CI,−0.27–0.73), respectively. Results of meta-regression analysis showed that the quality scores of papers and female sex ratios of participants did not affect the associations of VEGF concentrations with the risk of Alzheimer’s disease. However, the age average of patients significantly affects the associations of CSF VEGF concentrations with the risk of Alzheimer’s disease (P=0.051). There was a statistically significant subgroup effect for the disease severity of Alzheimer’s patients which modifies the associations of serum VEGF concentrations with the risk of Alzheimer’s disease (P<0.01) and subgroup analysis shows that study location modifies the associations of CSF and serum VEGF concentrations with the risk of Alzheimer’s disease (P<0.01).
Conclusion
The results show that the serum VEGF concentrations increased for Alzheimer’s patients in accordance with the increased expression of VEGF and the VEGF levels of Alzheimer’s patients decreased by increasing their disease severities. Therefore, in addition to detecting AD in the earliest stages of the disease, serum VEGF could be a promising biomarker to follow up on the disease and evaluate the clinical course of the disease.